DiaCarta Inc (DiaCarta) is a developer of molecular diagnostics products for cancer and infectious diseases. The company offers genomic testing for biomarkers and provides clinical sample testing services in their CLIA-certified lab. It offers products such as gene mutation detection kits, colon cancer tests, fusion gene detection tests, adapter dimer removal, DNA sample card, CRISPR gene editing, PCR ready lysis buffers and genotyping tests, among others. DiaCarta provides services including CLIA lab services; NGS target sequencing, next generation sequencing, companion diagnostics and CAR-T immunotherapy. The company markets its products through a channel of network distributors. It serves in Germany, Egypt, Iran, Turkey, Iraq, and Costa Rica. DiaCarta is headquartered in Pleasanton, California, The US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company DiaCarta Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- DiaCarta Inc Company Overview
- DiaCarta Inc Company Snapshot
- DiaCarta Inc Pipeline Products and Ongoing Clinical Trials Overview
- DiaCarta Inc - Pipeline Analysis Overview
- DiaCarta Inc - Key Facts
- DiaCarta Inc - Major Products and Services
- DiaCarta Inc Pipeline Products by Development Stage
- DiaCarta Inc Ongoing Clinical Trials by Trial Status
- DiaCarta Inc Pipeline Products Overview
- Companion Diagnostic Test - Cancer
- Companion Diagnostic Test - Cancer Product Overview
- Next Generation HPV Genotyping E6/E7 mRNA Test
- Next Generation HPV Genotyping E6/E7 mRNA Test Product Overview
- QuantiVirus Anti-SARS-CoV-2 IgG Test
- QuantiVirus Anti-SARS-CoV-2 IgG Test Product Overview
- QuantiVirus SARS-CoV-2 & Flu A/B Test
- QuantiVirus SARS-CoV-2 & Flu A/B Test Product Overview
- Quantivirus SARS-CoV-2 Antigen Rapid Home Test Kit
- Quantivirus SARS-CoV-2 Antigen Rapid Home Test Kit Product Overview
- QuantiVirus SARS-CoV-2 Multiplex Test Kit
- QuantiVirus SARS-CoV-2 Multiplex Test Kit Product Overview
- QuantiVirus SARS-CoV-2 Variant Detection Test
- QuantiVirus SARS-CoV-2 Variant Detection Test Product Overview
- RadTox QuantiDNA
- RadTox QuantiDNA Product Overview
- RadTox QuantiDNA Clinical Trial
- Rapid SARS-Cov-2 Variant Detection Test
- Rapid SARS-Cov-2 Variant Detection Test Product Overview
- TB Drug Resistance Mutation Test
- TB Drug Resistance Mutation Test Product Overview
- DiaCarta Inc - Key Competitors
- DiaCarta Inc - Key Employees
- DiaCarta Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- DiaCarta Inc, Recent Developments
- Mar 11, 2024: Florida Selects DiaCarta's cfDNA Test (RadTox) for Statewide Use to Detect Early Response of Cancer Treatment
- Dec 15, 2023: DiaCarta Obtains CLIA Approval For iCOLON iFOB Test
- Jul 24, 2023: DiaCarta and HMC/HML Team up for Customizing Lab Development Test Validations and Compliances in the US Market
- Apr 16, 2023: DiaCarta announces five abstracts accepted for presentation at AACR Annual Meeting 2023
- Jan 13, 2023: US FDA grants EUA for DiaCarta’s QuantiVirus MPXV test
- Jul 20, 2022: DiaCarta receives CE-IVD mark for its SARS CoV-2 Flu A/B combo test
- Apr 07, 2022: DiaCarta Expands Board Leadership with Industry Veteran
- Nov 30, 2021: DiaCarta's multivariant COVID-19 test accurately detects the Omicron variant
- Oct 27, 2021: DiaCarta's ColoScape assay detects precancerous colorectal cancer lesions and colorectal cancer mutations with high sensitivity
- Sep 09, 2021: DiaCarta receives CE/IVD for its new COVID 19 screening test that identifies delta plus and new variants
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- DiaCarta Inc Pipeline Products and Ongoing Clinical Trials Overview
- DiaCarta Inc Pipeline Products by Equipment Type
- DiaCarta Inc Pipeline Products by Indication
- DiaCarta Inc Ongoing Clinical Trials by Trial Status
- DiaCarta Inc, Key Facts
- DiaCarta Inc, Major Products and Services
- DiaCarta Inc Number of Pipeline Products by Development Stage
- DiaCarta Inc Pipeline Products Summary by Development Stage
- DiaCarta Inc Ongoing Clinical Trials by Trial Status
- DiaCarta Inc Ongoing Clinical Trials Summary
- Companion Diagnostic Test - Cancer - Product Status
- Companion Diagnostic Test - Cancer - Product Description
- Next Generation HPV Genotyping E6/E7 mRNA Test - Product Status
- Next Generation HPV Genotyping E6/E7 mRNA Test - Product Description
- QuantiVirus Anti-SARS-CoV-2 IgG Test - Product Status
- QuantiVirus Anti-SARS-CoV-2 IgG Test - Product Description
- QuantiVirus SARS-CoV-2 & Flu A/B Test - Product Status
- QuantiVirus SARS-CoV-2 & Flu A/B Test - Product Description
- Quantivirus SARS-CoV-2 Antigen Rapid Home Test Kit - Product Status
- Quantivirus SARS-CoV-2 Antigen Rapid Home Test Kit - Product Description
- QuantiVirus SARS-CoV-2 Multiplex Test Kit - Product Status
- QuantiVirus SARS-CoV-2 Multiplex Test Kit - Product Description
- QuantiVirus SARS-CoV-2 Variant Detection Test - Product Status
- QuantiVirus SARS-CoV-2 Variant Detection Test - Product Description
- RadTox QuantiDNA - Product Status
- RadTox QuantiDNA - Product Description
- RadTox QuantiDNA - Prospective Observational Exploratory Clinical Study to Determine the Assay Cut-off for the RadTox Test in Prostate Cancer Patients to Predict Gastrointestinal Radiation Toxicity Using Circulating Cell Free DNA Directly from Plasma
- Rapid SARS-Cov-2 Variant Detection Test - Product Status
- Rapid SARS-Cov-2 Variant Detection Test - Product Description
- TB Drug Resistance Mutation Test - Product Status
- TB Drug Resistance Mutation Test - Product Description
- DiaCarta Inc, Key Employees
- DiaCarta Inc, Other Locations
- Glossary
- DiaCarta Inc Pipeline Products by Equipment Type
- DiaCarta Inc Pipeline Products by Development Stage
- DiaCarta Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- BBC Entrepreneurial Training & Consulting LLC
- EnCor Biotechnology Inc
- Iovance Biotherapeutics Inc
